logo
Plus   Neg
Share
Email

Lilly Reports Positive Results From Taltz 5-yr Study - Quick Facts

Eli Lilly and Company (LLY) said the results from a five-year Phase 3 study for Taltz (ixekizumab) demonstrated that patients with moderate- to severe plaque psoriasis taking Taltz can achieve sustained skin clearance over the five-year treatment period. No unexpected safety outcomes were reported, the company said.

Later in the year, Eli Lilly plans to announce the results from IXORA-R, a clinical trial designed to evaluate superiority between Taltz and Tremfya (guselkumab) in adult patients with moderate- to severe plaque psoriasis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Kylie Cosmetics and Kylie Skin is set for a growth after the cosmetics company launched by Kylie Jenner in 2015 sold a major majority stake to beauty conglomerate Coty for $600 million. Jenner, who has been maintaining the full ownership of the company since its launch, sold 51 percent stake in Kylie... FedEx Corp. Chairman and CEO Fred Smith issued a challenge to the New York Times for publishing a "distorted and factually incorrect" story regarding corporate tax payments by the package delivery giant. The New York Times reported on Sunday that FedEx had made a major push for a reduction in corporate taxes when Donald Trump won the presidential election. A new study showed that foot traffic at Starbucks stores declined after the coffee giant changed to an 'open bathroom' policy. According to the study, store attendance per month at Starbuck stores declined 6.8 percent, relative to nearby restaurants and cafes, after the company made changes to its bathroom policy. In May 2018, Starbucks announced a new bathroom policy.
Follow RTT
>